These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26512597)

  • 1. Planned FDG PET-CT Scan in Follow-Up Detects Disease Progression in Patients With Locally Advanced NSCLC Receiving Curative Chemoradiotherapy Earlier Than Standard CT.
    Pan Y; Brink C; Schytte T; Petersen H; Wu YL; Hansen O
    Medicine (Baltimore); 2015 Oct; 94(43):e1863. PubMed ID: 26512597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial.
    Konert T; Vogel WV; Paez D; Polo A; Fidarova E; Carvalho H; Duarte PS; Zuliani AC; Santos AO; Altuhhova D; Karusoo L; Kapoor R; Sood A; Khader J; Al-Ibraheem A; Numair Y; Abubaker S; Soydal C; Kütük T; Le TA; Canh NX; Bieu BQ; Ha LN; Belderbos JSA; MacManus MP; Thorwarth D; Hanna GG
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2235-2243. PubMed ID: 31367906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
    Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL;
    Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor angiogenesis at baseline identified by
    Wei Y; Qin X; Liu X; Zheng J; Luan X; Zhou Y; Yu J; Yuan S
    J Transl Med; 2022 Feb; 20(1):63. PubMed ID: 35109866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Watch the weathercock: changes in re-staging 18F-FDG PET/CT scan predict the probability of relapse in locally advanced non-small cell lung cancer.
    Marquez-Medina D; Martin-Marco A; Popat S
    Clin Transl Oncol; 2016 Feb; 18(2):228-32. PubMed ID: 26203801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2).
    Vera P; Mezzani-Saillard S; Edet-Sanson A; Ménard JF; Modzelewski R; Thureau S; Meyer ME; Jalali K; Bardet S; Lerouge D; Houzard C; Mornex F; Olivier P; Faure G; Rousseau C; Mahé MA; Gomez P; Brenot-Rossi I; Salem N; Dubray B
    Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1057-65. PubMed ID: 24562641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
    Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
    Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy.
    Usmanij EA; de Geus-Oei LF; Troost EG; Peters-Bax L; van der Heijden EH; Kaanders JH; Oyen WJ; Schuurbiers OC; Bussink J
    J Nucl Med; 2013 Sep; 54(9):1528-34. PubMed ID: 23864719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
    AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort.
    Brose A; Michalski K; Ruf J; Tosch M; Eschmann SM; Schreckenberger M; König J; Nestle U; Miederer M
    Cancer Imaging; 2023 May; 23(1):45. PubMed ID: 37198668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interpretation and Prognostic Value of Positron Emission Tomography-Computed Tomography After Induction Chemotherapy With or Without Radiation in IIIA-N2 Non-small Cell Lung Cancer Patients Who Receive Curative Surgery.
    Kim SH; Lee JH; Lee GJ; Jeong S; Kwak YK; Kim HK; Cho DG; Park YH; Yu M; Yoon SC
    Medicine (Baltimore); 2015 Jun; 94(24):e955. PubMed ID: 26091460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial.
    Fleckenstein J; Hellwig D; Kremp S; Grgic A; Gröschel A; Kirsch CM; Nestle U; Rübe C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e283-9. PubMed ID: 21470782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
    Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
    Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K
    AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non-small cell lung cancer.
    Ebright MI; Russo GA; Gupta A; Subramaniam RM; Fernando HC; Kachnic LA
    J Thorac Cardiovasc Surg; 2013 Mar; 145(3):709-15. PubMed ID: 23317944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When is it best to repeat a 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan on patients with non-small cell lung cancer who have received neoadjuvant chemoradiotherapy?
    Cerfolio RJ; Bryant AS
    Ann Thorac Surg; 2007 Oct; 84(4):1092-7. PubMed ID: 17888953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC).
    Decoster L; Schallier D; Everaert H; Nieboer K; Meysman M; Neyns B; De Mey J; De Grève J
    Lung Cancer; 2008 Oct; 62(1):55-61. PubMed ID: 18394750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.